Biologics development and manufacturing built on product experience

TaiMed's CDMO capabilities are grounded in the same biologics development experience used to advance our own monoclonal antibody programs. From process and analytical development through cGMP manufacturing and regulatory support, our team works with biopharmaceutical partners to move antibody programs efficiently from development toward commercialization.

From molecule to market
TaiMed provides integrated CDMO services for monoclonal antibody and biologics programs, with flexible engagement models designed to support development at different stages.

Process Development
Upstream and downstream process development and optimization designed to support scalable biologics manufacturing.

Formulation Development

Formulation and stability development to support product performance, storage, and clinical or commercial requirements.

Analytical Development

Analytical method development, qualification/validation, product characterization, and stability testing.

cGMP Manufacturing

Single-use manufacturing capabilities supporting clinical and commercial biologics production.

Regulatory Support

CMC and regulatory support informed by TaiMed's own experience advancing a monoclonal antibody through global development and commercialization.
Experience behind the capabilities

TaiMed has developed, manufactured, and commercialized proprietary monoclonal antibody products, including Trogarzo®. That product experience gives our CDMO team a practical perspective on the scientific, quality, regulatory, and operational requirements that shape successful biologics development.

TaiMed’s cGMP facility

Our cGMP facility utilizes single-use technology, offering cost-effective and versatile manufacturing that complies with global regulations. Our services span from pilot scale to full commercialization for monoclonal antibody development. TaiMed is your one-stop integrated solution for all your needs.

Facility Highlights:

  • Approximately 60,000 square feet supporting cGMP operations.
  • Single-use upstream and downstream manufacturing technologies.
  • Quality-control capabilities supporting material/product release and stability analysis.
  • Controlled storage for drug substance and drug product across refrigerated, frozen, and controlled-room-temperature conditions.